Praxis Precision Medicines, Inc. (NASDAQ:PRAX – Get Rating) – Stock analysts at Wedbush dropped their FY2026 earnings per share estimates for Praxis Precision Medicines in a research note issued on Tuesday, May 10th. Wedbush analyst L. Chico now expects that the company will post earnings of $1.95 per share for the year, down from their prior estimate of $2.22.
Praxis Precision Medicines (NASDAQ:PRAX – Get Rating) last released its quarterly earnings results on Monday, May 9th. The company reported ($1.51) earnings per share for the quarter, missing the consensus estimate of ($1.29) by ($0.22). During the same period last year, the company posted ($0.71) EPS.
Shares of PRAX stock opened at $9.21 on Wednesday. The company has a market capitalization of $419.11 million, a price-to-earnings ratio of -2.37 and a beta of 2.04. Praxis Precision Medicines has a one year low of $7.25 and a one year high of $27.51. The company’s fifty day moving average price is $10.23 and its 200-day moving average price is $14.84.
Large investors have recently bought and sold shares of the company. Janus Henderson Group PLC raised its stake in shares of Praxis Precision Medicines by 10.1% during the 3rd quarter. Janus Henderson Group PLC now owns 3,279,165 shares of the company’s stock worth $60,626,000 after acquiring an additional 300,680 shares in the last quarter. BlackRock Inc. raised its position in shares of Praxis Precision Medicines by 16.4% in the fourth quarter. BlackRock Inc. now owns 2,496,696 shares of the company’s stock valued at $49,184,000 after buying an additional 352,027 shares during the last quarter. Alliancebernstein L.P. grew its holdings in shares of Praxis Precision Medicines by 13.9% in the fourth quarter. Alliancebernstein L.P. now owns 1,873,510 shares of the company’s stock valued at $36,908,000 after purchasing an additional 228,502 shares during the period. Point72 Asset Management L.P. grew its holdings in shares of Praxis Precision Medicines by 27.2% in the fourth quarter. Point72 Asset Management L.P. now owns 1,446,393 shares of the company’s stock valued at $28,494,000 after purchasing an additional 309,398 shares during the period. Finally, State Street Corp boosted its stake in Praxis Precision Medicines by 149.6% during the fourth quarter. State Street Corp now owns 1,267,815 shares of the company’s stock worth $24,976,000 after buying an additional 759,911 shares during the period. Institutional investors and hedge funds own 96.25% of the company’s stock.
Praxis Precision Medicines Company Profile (Get Rating)
Praxis Precision Medicines, Inc, a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor.
- Get a free copy of the StockNews.com research report on Praxis Precision Medicines (PRAX)
- Fifth Third Bancorp Stock Bestows Opportunity
- 3 Reasons Why Hostess Brands Could Be a Sweet Addition to Your Watchlist
- XPO Logistics Is A Logical Choice For Investors
- 3 Online Education Stocks Investors Should Study
- If PetMeds Is A Good Buy There Will Be A Better Signal
Receive News & Ratings for Praxis Precision Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Praxis Precision Medicines and related companies with MarketBeat.com's FREE daily email newsletter.